Editor for The Biotech Forum (www.biotechforumsa.com), the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade. For Free weekly investment reports on small, attractive biotech stocks just register at www.bretjenseninvests.com
RJ Chopin is an Equities Strategist and veteran trader/investor with over 19 years experience. RJ entered the stock market during late 90’s as a day-trader. After 3 years of high frequency day-trading, RJ began developing “Advanced Trading Concepts,” a proprietary step-by-step trading system involving equities profiling. RJ employs an esoteric analytical approach that involves company fundamentals, metric assessments and projections, technical analysis, volume analysis, behavioral identification, perceived market attitudes and other analytical criteria to profile and value risk/reward strategies. In 2008 RJ began publishing financial commentary for Seeking Alpha. He is a relentless advocate for investor responsibility, RJ advocates researching a company’s fundamentals, both historical and projected before investing. His insightful approach to equities trading and investing is reflected in his factual and analytical commentary. His didactic communication style is both interesting and informative. With refreshing clarity he makes sense of equity profiling. He is a staunch advocate for portfolio diversification.
Led by MIT engineers and Wall Street analysts, Trefis.com helps you understand how a company's products, that you touch, read, or hear about everyday, impact its stock price.
Surprisingly, the founders of Trefis discovered that along with most other people they just did not understand even the seemingly familiar companies around them: Apple, Google, Coca Cola, Walmart, GE, Ford, Gap, and others.
This might include you though you may have invested money in these companies, or may have been working with one of them for years as an employee, or have consulted with them as an expert for a long time.
Consider these questions:
•What % of Apple's stock price is iPhones? (Q: Is it 5%, 25%, or 50%?)
•What % of Dell's stock price is Dell Notebooks?
•If Bing took half the market share from Google Search, what % upside could there be for Microsoft’s stock?
On Trefis you will get answers to questions like above.
You can play with assumptions, or try scenarios, as-well-as ask questions to other users and experts. The platform uses extensive data to show in a single snapshot what drives the value of a company's business.
Trefis makes the same content, data, and tools that are currently available only to professional investors today, accessible to everyone. Importantly, it makes the extensive data/tools easy to use and understand, allowing investors to leverage the platform in their decision making much more efficiently than anything else available.
Trefis is currently used by hundreds of thousands of investors, company employees, and business professionals.
Renee Ann Butler is a freelance finance writer and former management consultant with over 15 years of experience in business management and strategy. She earned an MBA in financial management from Exeter in 2007 and has enjoyed a variety of international business experiences, working primarily with companies in England and Australia. Butler's work is centered on retail stocks and consumer trends. Her writing has appeared on TheStreet, Marketwatch, Insider Monkey, Seeking Alpha and Motley Fool.
Charts Don't Lie, People Do!
I made my first investment in 1987 while I was still in graduate school. I bought a few hundred shares of Crazy Eddie (CRZY) and within a months or so the the stock market crashed. I got out with a big loss and later Crazy Eddie went belly-up in 1989. What I have learned from this experience is that studying value line, reading investor's daily and watching FNN can't really help me uncover the true extent of CRZY's fraud and can't warn me about incoming Black Monday. As a biochemist my scientific background finally led me to technical analysis. I believe that I have found something that I can understand and something that will never lie to me.
Nowadays all my investment decisions are based on my charts. I am a long term trend follower and I especially like the most hated stocks with a prolonged bear market. I am looking for signs of a bottom, trend reversal or breakout using some of the indicators I developed over the years.
My education background is in Biological Science with a MS and a PH.D in Biochemistry. I had worked for pharmaceutical industries for 15+ years and published a few research papers with a Nobel Laureate prior to him winning the prize.
I only look at stocks that have the possibility to double over a twelve month period and stocks in which the risk/reward ratio payout is high. In addition I focus on swing trade opportunities.
I focus more on valuations and risk/reward metrics as opposed to what make companies tick.
I have been a professional investor for over 20 years and during the past several years an economics analyst and financial writer for capital.gr, the biggest economic news portal in Greece.
I have managed money from time to time and have also done some seed venture capital projects in the past.
I enjoy many hobbies and have had a passion for the stock market and finance since I was in my teens. I spent many years as an inventory auditor and I have a strong belief that the tedious hours of staring at charts, tables, and patterns; truly trained me to be a good investor.
TechCrunch (http://www.techcrunch.com/), founded on June 11, 2005, is a weblog dedicated to obsessively profiling and reviewing new Internet products and companies. In addition to covering new companies, we profile existing companies that are making an impact (commercial and/or cultural) on the new web space. TechCrunch is co-edited by Michael Arrington and Erick Schonfeld.
I founded Seeking Alpha, and lead it for its first 10 years until I passed the CEO role to Eli Hoffmann. I started Seeking Alpha after working for five years as a technology research analyst for Morgan Stanley in New York. Seeking Alpha is now the dominant crowdsourced equity research platform.
I wrote the ETF Investment Guide (http://seekingalpha.com/article/15136-etf-investing-guide-one-page-summary-of-the-entire-guide), and I blog about startup best practices at http://davidjaxon.wordpress.com .
I have a B.A from Oxford University and an MSc from The London School of Economics, and am married with five children.
Our small-cap hedge fund strategy beat the market by 44 percentage points since its inception 18 months ago. Visit our website to learn how you can do the same. Insider Monkey is a finance website that provides free hedge fund and insider trading data. We believe ordinary investors can beat the market by imitating insiders and best hedge fund managers. They have access to better information and experts than ordinary investors do. Take advantage of the SEC filings where hedge funds and insiders disclose their stock transactions.
Here is our team:
Ms. Krishnamsetty is the Editor of Insider Monkey. Prior to creating Insider Monkey with Dr. Dogan, Ms. Krishnamsetty was Associate Producer at Bloomberg Television. Prior to that, Ms. Krishnamsetty was on the afternoon news team at CNBC. Additionally, Ms. Krishnamsetty reported for NPR and worked as a risk management consultant at Marsh & McLennan. Ms. Krishnamsetty has a M.S. in Journalism from Columbia University’s Graduate School of Journalism.
Insider Monkey’s hybrid evaluation system ...More was created in 2003 by Dr. Ian Dogan. Dr. Dogan has a Ph.D. in financial economics with a specialization in insider trading. Dr. Dogan has provided consulting services to institutional investors and hedge funds, and managed a $200+ million fund using a strategy he developed utilizing insider transactions. Dr. Dogan recently authored the insider trading chapter of soon to be published “The Handbook of Investment Anomalies” by Zacks Investment Research. Insider Monkey will serve the outcome of the methodologies developed by Dr. Dogan to ordinary investors who don’t have access to academic quality research and tools to shape their investments.
For your inquiries please contact us at email@example.com
Chris earned the Chartered Market Technician designation. He is earning the Chartered Financial Analyst designation and graduated with honors in Economics. Also, he has managed money as a professional trader and independently, and continues to do so. Chris utilizes Technical, Financial Analysis and Behavioral Finance to select his investments. His analysis has been on Bloomberg and ZeroHedge.
Chief Market Strategist at www.buysellshort.net. Learn how to make a living trading small and midcap stocks
Additional Disclaimer: I may buy and sell any positions mentioned in any article at any time.
I am currently employed as a biologist and most of my work is in applied sciences. I have been trading on and off for the past few years mostly looking at companies in the Bio Science field, pharmacology, and some IT.
Mike Havrilla is a former pharmacist (retail and home infusion settings), biotech stock trader, and writer with experience that includes full-time online trading since 2009, working as a full-time pharmacist from 2004-2009, and writing for investors since 2007. Mike holds Doctor of Pharmacy (PharmD) and Bachelor of Science (Biology) degrees from the University of Pittsburgh and worked in the pharmaceutical industry for Wyeth prior to pharmacy school. He is also an avid runner and has completed over 20 marathons with a personal best time under three hours for the 26.2 mile race and under 80 minutes for the half marathon. Mike merged his former publishing business with BioRunUp.com / Mark Messier in October 2010, creating a new online biotech stock research and trading subscription service.
Michael is a Managing Director and Head of Investment Banking with T.R. Winston & Company.
Michael has enjoyed a 20+ year career in healthcare asset management, investment banking and in industry. Prior to moving to the buyside in 1999, Michael was Director, Biotechnology and Pharmaceutical Investment Banking at Merrill Lynch & Co. in New York.
Michael holds an M.P.H. in Health Policy and Management from Columbia University and an A.B. in Biology from Brandeis University in Massachusetts.
M.E. Garza is one of the founders of the biotech and healthcare sector news portal BioMedReports.com. He believes in getting the news from credible sources on the street and often reaches out to CEOs and newsmakers directly for interviews and discussions about their companies. Since he began publishing in 2008, Garza has built a reputation as a writer and reporter who can move markets. His track record for accurately reporting rumors and alerting readers about developments in the biotech/healthcare sector is unmatched during that time.